Why Some People Respond Less to GLP-1 Medicines

GLP-1 medicines produce large average benefits in clinical trials, yet some people lose much less weight than expected. That doesn't automatically mean they did something wrong. Even in trials, response is spread out: in STEP 1, about 86% of adults without diabetes taking semaglutide 2.4 mg lost at least 5% of their body weight by week 68, which also means roughly 1 in 7 did not. Averages hide a wide range.

What research links to lower response

A 2026 systematic review in Obesity Reviews pulled together studies on low or no weight-loss response to GLP-1 and GIP-based medicines. Factors associated with smaller weight loss included:

• higher starting body weight or BMI
• type 2 diabetes, higher HbA1c and insulin resistance
• male sex and older age
• shorter time on treatment and lower adherence (more months on treatment was linked with more weight loss)
• lifestyle factors such as diet and activity
• possibly genetics (for example, variants in the GLP-1 receptor gene) and the gut microbiome, though that evidence is still emerging

These are patterns across groups, not a diagnostic checklist for one person. The same factor may matter differently across medicines, populations and study designs, and no online quiz can explain why a particular person's response is small. If you live with type 2 diabetes, there's more on why weight-loss outcomes can differ with diabetes.

Why clinical trials and real life can differ

Trials have eligibility criteria, regular visits and structured support. In everyday care, cost, coverage, shortages, side effects, work schedules or trouble reaching a prescriber can interrupt treatment. A two-year cohort from a US Midwest health system followed 853 people prescribed a GLP-1 for class 2–3 obesity: about a quarter never started, and over a third stopped within two years. Those who stayed on treatment lost 9.2% of their weight on average, less than headline trial results. It's one health system, but it shows the gap between results under study conditions and results in everyday life.

What can be reviewed constructively?

A prescriber can look at the product and why it was prescribed, time on treatment, the prescribed schedule, any interruptions, other medicines, health conditions and the specific outcome being assessed. Ask what counts as a meaningful response for you and when it will be reassessed (see what counts as a response to weight-loss medication). Don't try to push past a limited response by taking extra doses, shortening intervals or buying unregulated products.

What "nonresponder" should not mean

It shouldn't be an identity, or a conclusion drawn from one month of readings. It's a clinical question about a specific treatment and outcome over a reasonable timeframe. Some people do better with a different plan or medicine, and that decision needs an individual medical review.

The research message is hopeful and realistic: these medicines help many people, not everyone responds the same way, and a disappointing response deserves curiosity rather than blame.